688319 Stock Overview
Engages in the research and development, production, and sale of human vaccines.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 688319 from our risk checks.
Chengdu Olymvax Biopharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.92 |
| 52 Week High | CN¥22.88 |
| 52 Week Low | CN¥7.06 |
| Beta | 0.50 |
| 11 Month Change | 1.48% |
| 3 Month Change | 5.06% |
| 1 Year Change | -45.48% |
| 33 Year Change | -72.35% |
| 5 Year Change | n/a |
| Change since IPO | -77.64% |
Recent News & Updates
What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You
Jun 24
Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?
May 28Recent updates
What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You
Jun 24Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?
May 28Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Apr 18These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26Shareholder Returns
| 688319 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.5% | -1.7% | -0.7% |
| 1Y | -45.5% | -20.9% | -19.1% |
Return vs Industry: 688319 underperformed the CN Biotechs industry which returned -20.9% over the past year.
Return vs Market: 688319 underperformed the CN Market which returned -19.1% over the past year.
Price Volatility
| 688319 volatility | |
|---|---|
| 688319 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 688319 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688319's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 471 | Shaowen Fan | www.olymvax.com |
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sale of human vaccines. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and Staphylococcus aureus, which is in Phase 3 clinical trial.
Chengdu Olymvax Biopharmaceuticals Inc. Fundamentals Summary
| 688319 fundamental statistics | |
|---|---|
| Market cap | CN¥3.69b |
| Earnings (TTM) | -CN¥12.29m |
| Revenue (TTM) | CN¥500.05m |
7.2x
P/S Ratio-294.5x
P/E RatioIs 688319 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688319 income statement (TTM) | |
|---|---|
| Revenue | CN¥500.05m |
| Cost of Revenue | CN¥34.93m |
| Gross Profit | CN¥465.12m |
| Other Expenses | CN¥477.41m |
| Earnings | -CN¥12.29m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 93.02% |
| Net Profit Margin | -2.46% |
| Debt/Equity Ratio | 33.0% |
How did 688319 perform over the long term?
See historical performance and comparison